Eli Lilly shares rise on positive retatrutide data
Eli Lilly shares gained 4% after the company presented trial data for its next-generation weight-loss drug retatrutide at the American Diabetes Association meeting. Analysts noted that the 4mg dose produced weight loss comparable to current high-dose therapies while maintaining manageable tolerability levels.
Xurve View
Insights:
Xurve View
ELI LILLY & CO shares rose 4% premarket on June 8 following positive trial data for its next-generation obesity drug, retatrutide. The data suggests the drug could extend the lead of ELI LILLY & CO in the $200B obesity market by matching current top-tier efficacy at lower doses. For investors, these findings reinforce the company's competitive position as drugmakers increasingly compete on patient tolerability and dosing simplicity.
